Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

Clinical trial NCT05879367 · RECRUITING

Trial details

NCT number: NCT05879367
Sponsor: Orbus Therapeutics, Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Glioblastoma, IDH-wildtype Glioblastoma Glioblastoma Multiforme Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype GBM Astrocytoma Astrocytoma, IDH-Mutant

Start date: 2023-07-24
Primary completion: 2026-06-30
Enrollment: 66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.